Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

British Journal of Clinical Pharmacology

Volumn 81, Issue 2, 2016, Pages 235-245

  De Vries, Ronald ^a   Smit, Johan W ^a   Hellemans, Peter ^a   Jiao, James ^b   Murphy, Joseph ^b   Skee, Donna ^b   Snoeys, Jan ^a   Sukbuntherng, Juthamas ^c   Vliegen, Maarten ^a   De Zwart, Loeckie ^a   Mannaert, Erik ^a   De Jong, Jan ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c PHARMACYCLICS INC   (United States)

Author keywords

absolute bioavailability; Bruton's tyrosine kinase; CYP3A; grape fruit juice; ibrutinib; stable isotope labelled microdosing

Indexed keywords

CARBON 13; DICLOFENAC; IBRUTINIB; PARACETAMOL; ANTINEOPLASTIC AGENT; CARBON; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; ARTICLE; BACKACHE; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MICRODOSE; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; HYPERVENTILATION; ISOTOPE LABELING; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; TENNIS ELBOW; ADOLESCENT; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; FRUIT AND VEGETABLE JUICE; GRAPEFRUIT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON ISOTOPES; CITRUS PARADISI; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; FRUIT AND VEGETABLE JUICES; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; TIME FACTORS; YOUNG ADULT;

EID: 84954556793     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12787     Document Type: Article

References (34)

1. Brown JR,. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 110-8.
2. Shanafelt T,. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program 2013; 2013: 158-67.
3. Burger JA,. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 2014; 9: 44-9.
4. Wiestner A,. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 88-96.
5. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ,. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014; 123: 1207-13.
6. IMBRUVICA® prescribing information. Pharmacyclics, Inc. Revised July 2014.
7. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH,. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
8. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonzalez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S,. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15: 1090-9.
9. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S,. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
10. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA,. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-16.
11. de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao J,. Effect of CYP3A perpetrators on ibrutinib exposure in normal healthy subjects. Pharma Res Per 2015; 3: e00156.
12. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A,. Absorption, metabolism and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men submitted to drug metabolism and disposition. Drug Metab Dispos 2015; 43: 289-97.
13. de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC, James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E,. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol 2015; 75: 907-16.
14. Marasanapalle VP, Boinpally RR, Zhu H, Grill A, Tang F,. Correlation between the systemic clearance of drugs and their food effects in humans. Drug Dev Ind Pharm 2011; 37: 1311-7.
15. Seidegard J, Nyberg L, Borga O,. Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. Eur J Pharm Sci 2012; 46: 530-6.
16. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA,. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003; 74: 121-9.
17. Guo LQ, Fukuda K, Ohta T, Yamazoe Y,. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000; 28: 766-71.
18. Lundahl J, Regardh CG, Edgar B, Johnsson G,. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995; 49: 61-7.
19. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB,. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83: 1097-105.
20. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB,. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33.
21. Seidegard J, Randvall G, Nyberg L, Borga O,. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. Pharmazie 2009; 64: 461-5.
22. Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y,. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000; 67: 201-14.
23. ICH-M3. ICH Topic M3 (R2). Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. International Conference on Harmonization of technical Requirements for Registration of Pharmacueticals for Human Use 2009.
24. Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu XS, Lacreta F,. Simultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 2013; 75: 763-8.
25. Gu H, Wang J, Aubry AF, Jiang H, Zeng J, Easter J, Wang JS, Dockens R, Bifano M, Burrell R, Arnold ME,. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Anal Chem 2012; 84: 4844-50.
26. Jiang H, Zeng J, Li W, Bifano M, Gu H, Titsch C, Easter J, Burrell R, Kandoussi H, Aubry AF, Arnold ME,. Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay. Anal Chem 2012; 84: 10031-7.
27. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ,. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7: 267-86.
28. Widmer W, Haun C,. Variation in furanocoumarin content and new furanocoumarin dimers in commercial grapefruit (Citrus paradisi Macf.) juices. J Food Sci 2005; 70: C307-12.
29. Fukuda K, Guo L, Ohashi N, Yoshikawa M, Yamazoe Y,. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr B Biomed Sci Appl 2000; 741: 195-203.
30. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y,. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 2003; 18: 365-72.
31. Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M, Vega JM,. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66: 358-66.
32. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE,. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831-9.
33. Guidance to the conduct of exploratory (phase 0) trials in Belgium (FAGG, version 2, January 2012) [online]. Available at http://www.fagg-afmps.be (last accessed 24 June 2015).
34. Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I,. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol 2015; 75: 111-21.